These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 27680223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report].
    Bassetti BR, Trés ES, Ciríaco JG, Pinto Neto LF.
    Rev Soc Bras Med Trop; 2010; 43(1):89-91. PubMed ID: 20305976
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Guillain-Barré syndrome during treatment with interferon alpha for hepatitis B.
    Boz C, Ozmenoglu M, Aktoz G, Velioglu S, Alioglu Z.
    J Clin Neurosci; 2004 Jun; 11(5):523-5. PubMed ID: 15177399
    [Abstract] [Full Text] [Related]

  • 7. A rare complication of pegylated interferon Alfa 2a in a hepatitis C-positive patient on maintenance hemodialysis.
    Satish R, Gokulnath, Mathew T.
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):139-42. PubMed ID: 22237239
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report.
    Liu Y, Chen H, Xu ZY.
    Medicine (Baltimore); 2023 Apr 07; 102(14):e33378. PubMed ID: 37026950
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.
    Antivir Ther; 2013 Apr 07; 18(1):57-64. PubMed ID: 22872648
    [Abstract] [Full Text] [Related]

  • 11. [Treatment with interferon-alpha 2a in a patient with chronic inflammatory demyelinating polyneuropathy].
    Ueda M, Ota K, Takeuchi M, Tsutsumi Y, Iwata M.
    Rinsho Shinkeigaku; 2000 Feb 07; 40(2):155-9. PubMed ID: 10835937
    [Abstract] [Full Text] [Related]

  • 12. Demyelinating polyneuropathy associated with chronic inactive hepatitis B infection.
    Babatin MA, AlJohani A.
    BMJ Case Rep; 2021 Mar 25; 14(3):. PubMed ID: 33766960
    [Abstract] [Full Text] [Related]

  • 13. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 25; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of combination therapy with peginterferon alfa-2alpha and bicyclol in chronic hepatitis B with high ALT levels].
    Ni Q, Tian-Sheng X, Min-Wei L, Ke-Zhou L.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Apr 25; 26(2):114-6. PubMed ID: 23002549
    [Abstract] [Full Text] [Related]

  • 15. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
    Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P.
    Hepatology; 2011 Nov 25; 54(5):1591-9. PubMed ID: 22045673
    [Abstract] [Full Text] [Related]

  • 16. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?
    Kozielewicz D, Zaleśna A, Dybowska D.
    Expert Opin Drug Saf; 2014 Aug 25; 13(8):1009-14. PubMed ID: 24930451
    [Abstract] [Full Text] [Related]

  • 17. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK.
    J Viral Hepat; 2013 Apr 25; 20(4):e115-23. PubMed ID: 23490379
    [Abstract] [Full Text] [Related]

  • 18. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong WM, Lo CM, Fan ST, Leung N, Lau GK, Hong Kong Liver Fibrosis Study Group.
    Aliment Pharmacol Ther; 2006 Apr 15; 23(8):1171-8. PubMed ID: 16611278
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May 15; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 20. Pegylated interferon induced myasthenia crisis--a case report.
    Congeni JP, Kirkpatrick RB.
    J Clin Neuromuscul Dis; 2013 Mar 15; 14(3):123-5. PubMed ID: 23492465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.